JPMorgan affiliates report 4.4% stake in REGENXBIO (RGNX) in 13G/A
Rhea-AI Filing Summary
JPMorgan Chase & affiliates reported beneficial ownership of 2,279,362 shares of REGENXBIO Inc. The filing, an amendment to a Schedule 13G/A, shows those shares represent 4.4% of the outstanding common stock (CUSIP 75901B107). The report attributes 2,104,445 shares of sole voting power and 2,279,362 shares of sole dispositive power. Multiple JPMorgan entities are named as holders. The filing is signed by a JPMorgan vice president.
Positive
- None.
Negative
- None.
Key Figures
Beneficial ownership: 2,279,362 shares
Percent of class: 4.4%
Sole voting power: 2,104,445 shares
+2 more
5 metrics
Beneficial ownership
2,279,362 shares
reported on Schedule 13G/A
Percent of class
4.4%
of REGENXBIO common stock
Sole voting power
2,104,445 shares
sole power to vote or direct the vote
Sole dispositive power
2,279,362 shares
sole power to dispose or direct disposition
CUSIP
75901B107
REGENXBIO common stock identifier
Key Terms
Schedule 13G/A, beneficially owned, sole dispositive power, parent holding company
4 terms
Schedule 13G/A regulatory
"Amendment No. 7 ) REGENXBIO Inc."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially owned regulatory
"Amount beneficially owned: 2,279,362"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive power regulatory
"Sole power to dispose or to direct the disposition of: 2,279,362"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
parent holding company regulatory
"Identification and Classification of the Subsidiary Which Acquired the Security"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stake does JPMorgan hold in REGENXBIO (RGNX)?
JPMorgan reports beneficial ownership of 2,279,362 shares, representing 4.4% of REGENXBIO common stock. The filing lists voting and dispositive powers and identifies multiple JPMorgan entities associated with the position.
Which JPMorgan entities are named in the Schedule 13G/A for RGNX?
The amendment names J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, and J.P. Morgan Investment Management Inc. as entities connected with the reported beneficial ownership position.
What document and dates are shown for JPMorgan's RGNX filing?
The excerpt is an Amendment No. 7 to a Schedule 13G/A referencing 05/29/2026 on the cover and signed on 06/04/2026 by a JPMorgan vice president, per the provided content.
Does the Schedule 13G/A indicate JPMorgan controls more than 5% of RGNX?
No. The filing states beneficial ownership is 4.4%, which is below the 5% threshold noted in the report. The form explicitly classifies the position as "Ownership of 5 percent or less of a class."